|Table of Contents|

Influences of DNA repair gene polymorphisms on clinical outcomes in advanced gastric cancer patients treated with XELOX chemotherapy

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2017 22
Page:
3631-3635
Research Field:
Publishing date:

Info

Title:
Influences of DNA repair gene polymorphisms on clinical outcomes in advanced gastric cancer patients treated with XELOX chemotherapy
Author(s):
Sun Hui; Fang Yueliang; Ji Lianhua; Cui Tingyun
Department of Oncology,Pukou Central Hospital,Jiangsu Nanjing 211800,China.
Keywords:
gastric cancer; XELOX chemotherapy; SNP polymorphism; survival
PACS:
R735.2
DOI:
10.3969/j.issn.1672-4992.2017.22.022
Abstract:
Objective:To investigated the associations between genetic polymorphisms of three genes involved in DNA repair and clinical outcomes in MGC patients receiving XELOX treatment.Methods:This retrospective study included 100 Chinese MGC patients receiving XELOX as first-line chemotherapy.Six single nucleotide polymorphisms (SNPs) of three genes (ERCC1 rs11615,ERCC2 rs13181 and rs1799793,and XRCC1 rs25487,rs25489,and rs1799782) were genotyped,and the associations between each SNP and clinical outcome were analyzed.Results:XRCC1 rs25487 A allele was significantly associated with progression disease (PD) to chemotherapy,and patients with GG genotype had significantly better progression-free survival (PFS) (8 months,95%CI：6.34~9.66,P＜0.05) compared with patients with the G allele (AA+GA).ERCC2 rs13181 G allele was significantly associated with PD,and TT homozygotes tended to have better PFS(7.46 months,95%CI：6.45~8.48,P＜0.05) than carriers (GG+GT).ERCC2 rs13181 G/T gene type were finally included in the COX regression model with a significance level of P＜0.05(HR=0.72,95%CI：0.53~0.97,P=0.025).Conclusion:These results suggest that the prognostic index comprising XRCC1 rs13181 polymorphisms may be a useful predictor of clinical outcomes in MGC treated with XELOX.

References:

［1］ Jemal A,Siegel R,Xu J,et al.Cancer statistics,2010［J］.CA Cancer J Clin,2010,60(5):277-300.
［2］ Nie Y,Wu K,Yu J,et al.A global burden of gastric cancer:the major impact of China［J］.Expert Rev Gastroenterol Hepatol,2017,10:1-11.
［3］Huang ZH,Hua D,Du X.Polymorphisms in p53,GSTP1 and XRCC1 predict relapse and survival of gastric cancer patients treated with oxaliplatin-based adjuvant chemotherapy［J］.Cancer Chemother Pharmacol,2009,64(5):1001-1007.
［4］ Liu B,Wei J,Zou Z,et al.Polymorphism of XRCC1 predicts overall survival of gastric cancer patients receiving oxaliplatin-based chemotherapy in Chinese population［J］.Europ J Human Genet:EJHG,2007,15(10):1049-1053.
［5］Xu J,Ma J,Zong HT,et al.Pharmacogenetic role of XRCC1 polymorphisms on the clinical outcome of gastric cancer patients with platinum-based chemotherapy:a systematic review and meta-analysis［J］.Genet Molec Res:GMR,2014,13(1):1438-1446.
［6］Sacerdote C,Guarrera S,Ricceri F,et al.Polymorphisms in the XRCC1 gene modify survival of bladder cancer patients treated with chemotherapy［J］.Int J Cancer J Int Cancer,2013,133(8):2004-2009.
［7］ He G,Chen G,Chen W,et al.Lack of association of XRCC1 rs1799782 genetic polymorphism with risk of pancreatic cancer:a Meta-analysis［J］ Tumour Biol,2014,35(5):4545-4550.
［8］ Cisneros L,Bussey KJ,Orr AJ,et al.Ancient genes establish stress-induced mutation as a hallmark of cancer［J］.PLoS One,2017,12(4):e0176258.
［9］ Zhang H,Ge J,Hong H,et al.Genetic polymorphisms in ERCC1 and ERCC2 genes are associated with response to chemotherapy in osteosarcoma patients among Chinese population:a Meta-analysis［J］.World J Surg Oncol,2017,15(1):75.
［10］ Chen L,Liu MM,Liu H,et al.ERCC1 and XRCC1 but not XPA single nucleotide polymorphisms correlate with response to chemotherapy in endometrial carcinoma［J］.Onco Targets Ther,2016,9:7019-7028.
［11］Ozcan MF,Dizdar O,Dincer N,et al.Low ERCC1 expression is associated with prolonged survival in patients with bladder cancer receiving platinum-based neoadjuvant chemotherapy［J］.Urol Oncol,2013,31(8):1709-1715.
［12］Wang Z,Chen JQ,Liu JL,et al.Polymorphisms in ERCC1,GSTs,TS and MTHFR predict clinical outcomes of gastric cancer patients treated with platinum/5-FU-based chemotherapy:a systematic review［J］.BMC Gastroenterol,2012,12:137.
［13］Lye MS,Visuvanathan S,Chong PP,et al.Homozygous wildtype of XPD K751Q polymorphism is associated with Increased risk of nasopharyngeal carcinoma in malaysian population［J］.PLoS One,2015,10(6):e0130530.
［14］ Dujowich M,Case JB,Ellison G,et al.Evaluation of low-dose ultraviolet light C for reduction of select ESKAPE pathogens in a canine skin and muscle model［J］.Photomed Laser Surg,2016,34(8):363-370.
［15］Xue H,Lu Y,Lin B,et al.The effect of XPD/ERCC2 polymorphisms on gastric cancer risk among different ethnicities:a systematic review and meta-analysis［J］.PLoS One,2012,7:e43431.
［16］Yin M,Yan J,Martinez-Balibrea E,et al.ERCC1 and ERCC2 polymorphisms predict clinical outcomes of oxaliplatin-based chemotherapies in gastric and colorectal cancer:a systemic review and meta-analysis［J］.Clin Cancer Res,2011,17:1632-1640.
［17］Giovannetti E,Pacetti P,Reni M,et al.Association between DNA-repair polymorphisms and survival in pancreatic cancer patients treated with combination chemotherapy［J］.Pharmacogenomics,2011,12:1641-1652.
［18］Mahimkar MB,Samant TA,Kannan S,et al.Polymorphisms in GSTM1 and XPD genes predict clinical outcome in advanced oral cancer patients treated with postoperative radiotherapy［J］.Mol Carcinog,2012,51(Suppl1):E94-E103.

Memo

Memo:
南京市医学科技发展项目(编号：YKK14183）
Last Update: 1900-01-01